CBD: Difference between revisions

From Glioblastoma Treatments
Jump to navigationJump to search
Visual
No edit summary
No edit summary
 
Line 1: Line 1:
{{TreatmentInfo
{{TreatmentInfo
|drug_name=CBD (Cannabidiol)
|drug_name=Sodium R Lipoate and Hydroxycitrate (METABLOC)
|overview=CBD is a non-psychoactive component of cannabis. It has shown potential therapeutic effects in cancer treatment, including anti-inflammatory, analgesic, and anti-nausea properties, as well as possible direct anti-tumor effects.
|FDA_approval=No (Used in investigational metabolic therapy for brain tumors)
|FDA_approval=Yes, for specific epilepsy syndromes; not FDA-approved for cancer treatment
|used_for=Investigational use in brain tumor treatment, including primary and metastatic gliomas
|used_for=Investigational use in cancer treatment, including symptom management and potential anti-tumor effects
|clinical_trial_phase=Early clinical evaluation in a small case series
|clinical_trial_phase=Preclinical studies and early human trials for cancer
|common_side_effects=Not specified in the provided information
|common_side_effects=Tiredness, diarrhea, changes in appetite/weight; generally well-tolerated at doses used for epilepsy
|OS_with=Varies; one GBM patient had a significant tumor shrinkage, others showed extended progression-free survival, including one patient surviving 87 months post-diagnosis
|OS_with=Not applicable; ongoing research into potential impacts on overall survival in cancer patients
|PFS_with=Majority of newly diagnosed patients without disease progression for periods extending to 2-3 years, and in one case, 87 months
|PFS_with=Not applicable; ongoing research into potential impacts on progression-free survival in cancer patients
|usefulness_rating=3
|usefulness_rating=4
|notes=This metabolic therapy, combining sodium R lipoate and hydroxycitrate, has shown promising outcomes in a small French study involving glioma patients. The therapy aims to disrupt cancer metabolism, potentially extending survival and reducing tumor size in some patients. While preliminary results are encouraging, particularly for patients with newly diagnosed gliomas, the need for well-conducted, larger-scale trials is emphasized to firmly establish efficacy and safety.
|treatment_category=Over-the-Counter Drugs and Supplements
|links=
|links=
|toxicity_level=2
|toxicity_level=2
|treatment_category=Nutraceuticals
|toxicity_explanation=The toxicity of Sodium R Lipoate and Hydroxycitrate (METABLOC) has been assessed as relatively low. It's still undergoing early clinical evaluation, which means it hasn't caused any severe adverse reactions to this point. However, we lack specific information on its common side effects. It's important to remember that everybody's body responds differently to medications, so while the toxicity appears low, some individuals may still experience side effects.
|toxicity_explanation=The toxicity level of CBD (Cannabidiol) is relatively low. It's been reported to be generally well-tolerated, especially at doses used for epilepsy. Typically, side effects may include tiredness, diarrhea, and changes in appetite or weight. However, as it is currently under investigational use in cancer treatment, including glioblastoma, the potential toxicities specific to cancer patients, particularly those with glioblastoma, are not fully understood and are currently under active research. It's essential to discuss with your healthcare provider before starting any new treatment regimen.
|overview=Sodium R Lipoate and Hydroxycitrate (METABLOC) is an investigational metabolic therapy for brain tumors, particularly gliomas, showing promising outcomes in early clinical evaluations, including significant tumor shrinkage and extended progression-free survival in some patients. While the therapy has a relatively low toxicity level and no severe adverse reactions reported thus far, further large-scale trials are needed to confirm its efficacy and safety.}}
|notes=CBD, a non-psychoactive component of cannabis, has been explored for its potential therapeutic effects in cancer treatment, including anti-inflammatory, analgesic, and anti-nausea properties, as well as possible direct anti-tumor effects. While preclinical studies have shown promising results, including inhibition of tumor growth and synergistic effects with chemotherapy in models of glioblastoma and other cancers,
conclusive evidence from clinical trials is needed to fully understand its efficacy and optimal use in cancer treatment.
 
=== Sativex (Nabiximols) and Glioblastoma ===
A Phase 1b trial investigated the combination of Sativex (nabiximols), a cannabis-based spray containing a 1:1 ratio of CBD and THC, with temozolomide (TMZ) chemotherapy in patients with recurrent glioblastoma. The study observed a significant improvement in one-year survival rates among patients treated with Sativex compared to the placebo group (83% versus 44%, respectively). This difference suggests that Sativex could enhance survival when combined with standard chemotherapy. However, researchers emphasize that these findings, while promising, need to be confirmed in larger, more robust clinical trials.<ref>{{Cite web |title=Clinical Trial: CBD
Doubles Brain Cancer Survival Rates |url=https://mysupplyco.com |publisher=My Supply Co. |accessdate=2024-08-12}}</ref>
 
=== Potential Mechanisms and Future Research ===
The effects of CBD in glioblastoma are thought to stem from its ability to inhibit tumor cell migration, invasion, and angiogenesis. CBD has shown potential in modulating the immune environment around the tumor, possibly enhancing the effectiveness of other treatments like chemotherapy. These preclinical findings, along with the initial clinical results, suggest a multi-targeted approach by CBD that could be beneficial in treating glioblastoma.<ref>{{Cite web |title=From bench to bedside: the application of cannabidiol in glioma |url=https://translational-medicine.biomedcentral.com |publisher=Journal of Translational Medicine |accessdate=2024-08-12}}</ref>
 
Further research, including ongoing and future trials, is necessary to fully understand the impact of CBD and THC-based treatments on overall survival in glioblastoma patients and to determine the best protocols for their use.<ref>{{Cite web |title=Developments in cannabis-based drug trial for glioblastomas |url=https://www.thebraintumourcharity.org |publisher=The Brain Tumour Charity |accessdate=2024-08-12}}</ref>
 
 
}}

Latest revision as of 01:19, 18 January 2025

Property Information
Drug Name Sodium R Lipoate and Hydroxycitrate (METABLOC)
Overview Sodium R Lipoate and Hydroxycitrate (METABLOC) is an investigational metabolic therapy for brain tumors, particularly gliomas, showing promising outcomes in early clinical evaluations, including significant tumor shrinkage and extended progression-free survival in some patients. While the therapy has a relatively low toxicity level and no severe adverse reactions reported thus far, further large-scale trials are needed to confirm its efficacy and safety.
FDA Approval No (Used in investigational metabolic therapy for brain tumors)
Used for Investigational use in brain tumor treatment, including primary and metastatic gliomas
Clinical Trial Phase Early clinical evaluation in a small case series
Clinical Trial Explanation Not specified
Common Side Effects Not specified in the provided information
OS without Not specified
OS with Varies; one GBM patient had a significant tumor shrinkage, others showed extended progression-free survival, including one patient surviving 87 months post-diagnosis
PFS without Not specified
PFS with Majority of newly diagnosed patients without disease progression for periods extending to 2-3 years, and in one case, 87 months
Usefulness Rating 3
Usefulness Explanation Not specified
Toxicity Level 2
Toxicity Explanation The toxicity of Sodium R Lipoate and Hydroxycitrate (METABLOC) has been assessed as relatively low. It's still undergoing early clinical evaluation, which means it hasn't caused any severe adverse reactions to this point. However, we lack specific information on its common side effects. It's important to remember that everybody's body responds differently to medications, so while the toxicity appears low, some individuals may still experience side effects.

Notes: This metabolic therapy, combining sodium R lipoate and hydroxycitrate, has shown promising outcomes in a small French study involving glioma patients. The therapy aims to disrupt cancer metabolism, potentially extending survival and reducing tumor size in some patients. While preliminary results are encouraging, particularly for patients with newly diagnosed gliomas, the need for well-conducted, larger-scale trials is emphasized to firmly establish efficacy and safety.


From Ben Williams Book: Not specified

Loading comments...
Retrieved from "http://glioblastomatreatments.wiki:80/index.php?title=CBD&oldid=94188"